NDAINTRAVENOUSSOLUTION
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
KYXATA (carboplatin) by Viatris (2) is platinum-based drug that binds to dna and forms dna cross-links. Approved for non-small cell lung cancer, cervical cancer, urothelial cancer. First approved in 2025.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYXATA (carboplatin) is a platinum-based chemotherapy agent that binds to DNA and forms cross-links, inhibiting replication and transcription to trigger cell death. It is indicated for non-small cell lung cancer, cervical cancer, and urothelial cancer via intravenous infusion. This is a recently approved generic formulation entering a mature competitive oncology market.
Launch18.9 years to LOE
As a newly launched generic formulation, this product faces immediate pricing pressure and limited growth potential in a commoditized chemotherapy space, suggesting smaller commercial team allocation.
Mechanism of Action
platinum-based drug that binds to DNA and forms DNA cross-links. These crosslinks inhibit DNA replication and transcription and trigger cytotoxic processes that lead to cell death.
Pharmacologic Class:
Platinum-based Drug
Indications (3)
Worked on KYXATA at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.